Virtu Financial LLC Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Virtu Financial LLC reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 29.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,294 shares of the biopharmaceutical company's stock after selling 1,760 shares during the quarter. Virtu Financial LLC's holdings in Regeneron Pharmaceuticals were worth $3,058,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of REGN. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. OFI Invest Asset Management purchased a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $28,000. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares in the last quarter. Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $36,000. Finally, Private Wealth Management Group LLC grew its stake in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 39 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

REGN has been the subject of several recent analyst reports. Sanford C. Bernstein lowered their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Canaccord Genuity Group cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, December 17th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. UBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $973.13.

Remove Ads

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded up $6.00 on Wednesday, hitting $640.14. 1,251,813 shares of the company's stock were exchanged, compared to its average volume of 639,898. The company has a 50-day simple moving average of $687.18 and a 200-day simple moving average of $806.20. Regeneron Pharmaceuticals, Inc. has a 1 year low of $630.62 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market capitalization of $69.98 billion, a PE ratio of 16.72, a PEG ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $11.86 earnings per share. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.